Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy

Kreps, E.O. ; Epps, S.J. ; Consejo, A. (Universidad de Zaragoza) ; Dick, A.D. ; Guly, C. M. ; Ramanan, A.V.

Resumen: Objectives
To examine the outcome of infliximab treatment in patients with non-infectious paediatric uveitis who have previously failed biologic treatment.

Methods
A retrospective cohort study was performed at Bristol Eye Hospital, UK. Paediatric patients with chronic non-infectious uveitis who had been switched to infliximab due to inadequate uveitis control were identified. Two separate groups were evaluated: group 1 consisted of 20 children (36 eyes) who had been switched to infliximab following treatment failure with adalimumab (=in-class switching), while group 2 (5 patients; 9 eyes) included those who had been switched to infliximab from a non-TNF antagonist after failing several biologics (=across-class switching). The change in anterior chamber (AC) activity between baseline and 6- and 24-months follow-up was the primary outcome measure.

Results
A statistically significant reduction in AC activity was found between baseline and 6-months follow-up (RE: p = 0.002; LE: p < 0.001) and between baseline and 24-months follow-up (RE: p = 0.016; LE: p = 0.011) in group 1. No statistically significant difference was found for either eye in the number of steroid eye drops needed between time points or the difference in visual acuity in time. In group 2, analysis of change of AC activity, number of steroid eye drops and visual acuity failed to reach statistical significance. Treatment failure occurred in four patients (20% of group 1) and adverse events developed in six patients including three patients with acute infusion reactions.

Conclusions
This study supports the efficacy and safety of infliximab in adalimumab-refractory patients with paediatric non-infectious uveitis.

Idioma: Inglés

DOI: 10.1038/s41433-023-02795-3

Año: 2023

Publicado en: Eye (Basingstoke) 38 (2023), 871–876
ISSN: 0950-222X

Factor impacto JCR: 2.8 (2023)

Categ. JCR: OPHTHALMOLOGY rank: 24 / 95 = 0.253 (2023) - Q2 - T1

Factor impacto CITESCORE: 6.4 - Ophthalmology (Q1) - Sensory Systems (Q1)

Factor impacto SCIMAGO: 1.373 - Arts and Humanities (miscellaneous) (Q1) - Sensory Systems (Q1) - Ophthalmology (Q1) - Medicine (miscellaneous) (Q1)

Tipo y forma: Article (Published version)

Área (Departamento): Área Física Aplicada (Dpto. Física Aplicada)